Stockreport

Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia

Selecta Biosciences, Inc.  (SELB) 
Last selecta biosciences, inc. earnings: 3/12 08:00 am Check Earnings Report
PDF WATERTOWN, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platf [Read more]